Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refratory of Ruxolitinib Treatment.
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This was a phase 2, single-arm, open-label, non-randomised, multicentre, study to evaluate
the efficacy and safety of Jaktinib in patients with myelofibrosis who were relapsed or
refractory of ruxolitinib treatment.